Ansbert Gadicke Sells 140,488 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 140,488 shares of the firm’s stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total value of $171,395.36. Following the sale, the insider directly owned 6,007,122 shares in the company, valued at approximately $7,328,688.84. This trade represents a 2.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total transaction of $121,341.27.
• On Friday, October 31st, Ansbert Gadicke sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Thursday, October 30th, Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $124,318.48.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Ansbert Gadicke sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total value of $113,271.52.
• On Monday, October 27th, Ansbert Gadicke sold 72,709 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total value of $125,059.48.

Werewolf Therapeutics Price Performance

Shares of HOWL opened at $1.15 on Friday. The business has a 50-day moving average of $1.60 and a 200-day moving average of $1.32. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 5.30. The company has a market capitalization of $55.82 million, a price-to-earnings ratio of -0.71 and a beta of 0.72. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.39.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOWL has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Bank of America cut their price target on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Finally, JMP Securities lowered their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of HOWL. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics during the second quarter worth $28,000. Vontobel Holding Ltd. bought a new stake in shares of Werewolf Therapeutics during the first quarter worth about $34,000. Qube Research & Technologies Ltd acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth about $48,000. Nuveen LLC bought a new position in Werewolf Therapeutics in the 1st quarter valued at about $71,000. Finally, AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the 1st quarter valued at about $79,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.